Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.32 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | MAT2A | P31153 | 1/20 | 0.30 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27759574 | 0.78 | GRM1 (0.36) | GRM1CYP11B1CYP3A4CYP2D6ELANE | |
| SCHEMBL30118921 | 0.76 | GAA (0.33) | — | |
| SCHEMBL29995220 | 0.76 | KDM4E (0.42) | GRM1 | |
| Benzene SCHEMBL28270966 | 0.75 | NAPRT (0.35) | GRM1 | |
| SCHEMBL5314044 | 0.74 | KDM4E (0.37) | GRM1 | |
| SCHEMBL29994720 | 0.72 | MYC (0.50) | CYP3A4KDM4D | |
| SCHEMBL28731814 | 0.71 | MYC (0.39) | CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL28935001 | 0.70 | MYC (0.38) | CYP3A4 | |
| SCHEMBL21722525 | 0.69 | GRM1 (0.45) | GRM1CYP11B1CYP3A4CYP2D6PARP1 | |
| SCHEMBL21722473 | 0.69 | KDM4E (0.47) | GRM1CYP3A4CYP2D6PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117377668-A | Inhalant formulations of PGDH inhibitors and methods of use thereof | 迈欧伏特治疗公司 | 2024-01-09 | — | — | CN | disclosed |
| US-11739070-B2 | C5A receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2023-08-29 | — | — | US | disclosed |
| US-20230192708-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-22 | — | — | US | disclosed |
| US-11608341-B2 | Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2023-03-21 | — | — | US | disclosed |
| CN-115335043-A | PGDH inhibitors and methods of making and using | 迈欧伏特治疗公司 | 2022-11-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192708-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | C3AR1, C5AR1, C5AR2 | GRM1 1007/4885CYP11B1 1504/4885CYP3A4 513/4885 |
| US-11739070-B2 | C5A receptor modulators | C5AR1, C3AR1, C5AR2 | GRM1 964/4885CYP11B1 1510/4885CYP3A4 613/4885 |
| US-11608341-B2 | Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators | C5AR1, C3AR1, C5AR2 | GRM1 935/4885CYP11B1 2377/4885CYP3A4 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.